Credit: Stop TB PartnershipThe Global Antibiotic Research & Development Partnership (GARDP) and the Stop TB Partnership’s Global Drug Facility (GDF) announced a partnership agreement to improve global access to antibiotics. GDF will incorporate GARDP’s portfolio of antibiotics to improve appropriate and affordable antibiotic access for the benefit of patients and health systems, particularly in low- and middle-income countries.
The partnership between GARDP and GDF reflects the increasing need to respond to the crisis of antimicrobial resistance (AMR) through global coordination. TB is caused by the bacterium Mycobacterium tuberculosis. Like other bacteria, it can evolve to develop resistance to available treatments, making those treatments less effective in the population at large. Currently, GDF supports access to medications for all types of TB, including multidrug-resistant and extensively drug-resistant TB; now in partnership with GARDP, it is broadening its approach to antibiotics for drug-resistant infections more generally.
Full details about the partnership are available here.
For more TB updates, check out the latest edition of the TB Online Weekly Newsletter (#17, 31 May 2024).
The TB Online Weekly Newsletter is brought to you by TB CAB and EATG. Subscribe to the newsletter here.
Source : Stop TB Partnership
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.